June 05, 2007
Largest ever Phase III lung cancer trial based on LICR discovery
GSK has announced the launch of the largest ever Phase III trial in lung cancer treatment, which is based on the MAGE-A3 cancer-testis antigen discovered by the Ludwig Institute for Cancer Research. Results from a Phase II trial showed that the cancer vaccine, or ‘antigen-specific cancer immunotherapy (ASCI),’ showed a 27% reduction in the relative risk of recurrence of non-small cell lung cancer (NSCLC) following surgery.